Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Conditions: Hepatitis B, Chronic Interventions: Drug: Imdusiran; Drug: Durvalumab Sponsors: Arbutus Biopharma Corporation Not yet recruiting

Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials